The new Wegovy pill could help patients lose 17% of their body weight, clinical trial results show. 

The tablet version of Wegovy, approved in the UK by MHRA, is the first GLP-1 weight-loss pill licensed for weight management in the UK and is expected to become available from early July. 

Clinical trials show oral Wegovy can deliver an average weight loss of around 17% of body weight, compared to approximately 20.7% for injectable Wegovy and 22.5% for Mounjaro. 

According to Simple Online Healthcare, the pill could be priced at £99 ($132) a month, with thousands of patients already registering interest. 

“The effectiveness of semaglutide is already well established through injectable treatments,” said Abdal Alvi, Chief Clinical Officer at Simple Online Healthcare. “What changes here is the delivery method.” 

“For patients who are uncomfortable with injections or simply prefer taking a tablet, oral Wegovy offers another evidence-based treatment option. 

“We know there are many people who have been interested in weight-loss medication but have been reluctant to start because they did not want to self-inject.”